Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sweet Dream Oral Liquid (Meimeng Koufuye) is a Traditional Chinese Medicine (TCM) formulation widely used in China for the treatment of insomnia, anxiety, and neurasthenia. It is composed of multiple herbal extracts, including *Radix Rehmanniae*, *Radix Angelicae Sinensis*, and *Semen Ziziphi Spinosae*. In clinical research, it is being evaluated as an adjunctive therapy for patients with schizophrenia to alleviate side effects associated with long-term atypical antipsychotic use, such as hyperprolactinemia, sexual dysfunction, extrapyramidal symptoms, and cognitive impairment. The therapeutic effects are attributed to its ability to regulate the central nervous system, potentially through the modulation of GABAergic and serotonergic pathways, providing sedative, hypnotic, and neuroprotective benefits.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Sweet Dream Oral Liquid.